How cellular interactions in the tumor-immune microenvironment govern immunotherapy outcomes remains a major question in many cancers, in particular in those with high tumor heterogeneity. In particular the role of specific immune cell types and their spatial interactions have been recognized to differe significantly, even within cancer entities. These immunotypes of cancers are likely to have direct implications for patient care.
Highly-multiplexed mass-based deep spatial profiling using imaging mass cytometry (IMC) or multiplexed ion beam imaging (MIBI) uses a targeted approach for spatial proteomics by combining 40+ metal-isotope labelled antibodies for spatial analysis at lower than cellular resolution.
In this presentation I will highlight our recent advances in utilizing these methods for identifying clinically relevant spatial immunotypes in human cancer using bioinformatic deconvolution of spatial immune network architecture.
